The potential role of ANXA11/ANXA3 protein level ratio in predicting antidepressant treatment outcomes.

IF 3.7 3区医学 Q1 CLINICAL NEUROLOGY

European Archives of Psychiatry and Clinical Neuroscience Pub Date : 2025-09-16 DOI:10.1007/s00406-025-02117-6

Xiangjun Zhou, Yucai Qu, Lingyi Shi, Zhiqiang Du, Qin Zhou, Zhenhe Zhou, Ying Jiang, Haohao Zhu

{"title":"The potential role of ANXA11/ANXA3 protein level ratio in predicting antidepressant treatment outcomes.","authors":"Xiangjun Zhou, Yucai Qu, Lingyi Shi, Zhiqiang Du, Qin Zhou, Zhenhe Zhou, Ying Jiang, Haohao Zhu","doi":"10.1007/s00406-025-02117-6","DOIUrl":null,"url":null,"abstract":"Objective: To explore the causal relationship between 2,821 plasma protein level ratios and antidepressant treatment response to uncover the potential molecular mechanisms.Methods: We utilized the protein level ratio dataset from the UK Biobank Pharma Proteomics Project (UKB PPP) and the antidepressant treatment dataset from the Psychiatric Genomics Consortium. We employed Mendelian Randomization (MR) analysis to explore the causal relationships between 2,821 protein level ratios and antidepressant treatment. Additionally, we conducted GO/KEGG analysis to uncover associated biological processes, cellular components, molecular functions, and signaling pathways.Results: We found that the protein level ratio of ANXA11/ANXA3 was significantly positively associated with the positive effects of antidepressant treatment(IVW method(FEM): OR = 1.537, 95%CI = 1.263-1.869, p = 1.730E-05, pFDR = 0.049), suggesting its potential as a biomarker for predicting antidepressant efficacy. Moreover, the GO/KEGG analysis provided new insights into the genetic architecture and molecular mechanisms underlying antidepressant efficacy.Conclusion: Our results highlight the significance of protein level ratios in the pathophysiological processes of depression and offer novel strategies for the development of personalized treatment approaches. Future studies are warranted to further validate these findings and explore their clinical implications.","PeriodicalId":11822,"journal":{"name":"European Archives of Psychiatry and Clinical Neuroscience","volume":" ","pages":""},"PeriodicalIF":3.7000,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Archives of Psychiatry and Clinical Neuroscience","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00406-025-02117-6","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To explore the causal relationship between 2,821 plasma protein level ratios and antidepressant treatment response to uncover the potential molecular mechanisms.

Methods: We utilized the protein level ratio dataset from the UK Biobank Pharma Proteomics Project (UKB PPP) and the antidepressant treatment dataset from the Psychiatric Genomics Consortium. We employed Mendelian Randomization (MR) analysis to explore the causal relationships between 2,821 protein level ratios and antidepressant treatment. Additionally, we conducted GO/KEGG analysis to uncover associated biological processes, cellular components, molecular functions, and signaling pathways.

Results: We found that the protein level ratio of ANXA11/ANXA3 was significantly positively associated with the positive effects of antidepressant treatment(IVW method(FEM): OR = 1.537, 95%CI = 1.263-1.869, p = 1.730E-05, pFDR = 0.049), suggesting its potential as a biomarker for predicting antidepressant efficacy. Moreover, the GO/KEGG analysis provided new insights into the genetic architecture and molecular mechanisms underlying antidepressant efficacy.

Conclusion: Our results highlight the significance of protein level ratios in the pathophysiological processes of depression and offer novel strategies for the development of personalized treatment approaches. Future studies are warranted to further validate these findings and explore their clinical implications.

查看原文本刊更多论文

ANXA11/ANXA3蛋白水平比值在预测抗抑郁治疗结果中的潜在作用

目的：探讨2821血浆蛋白水平比值与抗抑郁药物治疗反应的因果关系，揭示其可能的分子机制。方法：我们利用来自英国生物银行制药蛋白质组学项目（UKB PPP）的蛋白质水平比率数据集和来自精神病学基因组学联盟的抗抑郁治疗数据集。我们采用孟德尔随机化（MR）分析来探讨2821种蛋白质水平比率与抗抑郁药物治疗之间的因果关系。此外，我们还进行了GO/KEGG分析，以揭示相关的生物过程、细胞成分、分子功能和信号通路。结果：我们发现ANXA11/ANXA3蛋白水平比值与抗抑郁治疗的积极效果显著正相关（IVW法（FEM）： OR = 1.537, 95%CI = 1.263-1.869, p = 1.730E-05, pFDR = 0.049），提示其有可能作为预测抗抑郁疗效的生物标志物。此外，GO/KEGG分析为抗抑郁药物疗效的遗传结构和分子机制提供了新的见解。结论：我们的研究结果强调了蛋白质水平比值在抑郁症病理生理过程中的重要性，并为个性化治疗方法的发展提供了新的策略。未来的研究需要进一步验证这些发现并探索其临床意义。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European Archives of Psychiatry and Clinical Neuroscience 医学-精神病学

CiteScore

8.80

自引率

4.30%

发文量

154

审稿时长

6-12 weeks

期刊介绍： The original papers published in the European Archives of Psychiatry and Clinical Neuroscience deal with all aspects of psychiatry and related clinical neuroscience. Clinical psychiatry, psychopathology, epidemiology as well as brain imaging, neuropathological, neurophysiological, neurochemical and moleculargenetic studies of psychiatric disorders are among the topics covered. Thus both the clinician and the neuroscientist are provided with a handy source of information on important scientific developments.